Search

Displaying results 8061 - 8070 of 10000 in total
  1. Drug

    Elsamitrucin

    go.drugbank.com/drugs/DB05129
    Investigational

    The cytostatic agent Elsamitrucin is a new fermentation product active in a variety of in vivo tumor models of murine and human origin. (PMID: 8150873)

  2. Drug

    Acediasulfone

    go.drugbank.com/drugs/DB08926
    Experimental

    Acediasulfone (INN) is an antimicrobial and antimalarial long-acting prodrug of dapsone.

  3. Drug

    N-oleoyldopamine

    go.drugbank.com/drugs/DB17036
    Experimental

    N-oleoyldopamine (OLDA) is an amide of dopamine and oleic acid.[A253042]

  4. Drug

    SRT-1720

    go.drugbank.com/drugs/DB17057
    Experimental

    SRT-1720 is an activator of NAD(+)-dependent histone deacetylase SIRT1.[A253147]

  5. Drug

    Edralbrutinib

    go.drugbank.com/drugs/DB18095
    Investigational

    Edralbrutinib is an orally available small molecule inhibitor of Bruton's tyrosine kinase.

    Synonyms: 4-amino-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-1-((3r)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7h-pyrrolo(2,3-d)pyridazin-7-one, 7h-pyrrolo(2,3-d)pyridazin-7-one, 4-amino-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-1-((3r)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-
  6. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.

  7. Drug

    AG-24322

    go.drugbank.com/drugs/DB13035
    Investigational

    AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.

  8. Drug

    AMT-080

    go.drugbank.com/drugs/DB17846
    Experimental

    AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.

  9. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. … Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

  10. Drug

    GALE-301

    go.drugbank.com/drugs/DB17262
    Investigational

    It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171] … GALE-301 is an investigational cancer immunotherapy.